National Cancer Institute (NCI): Intestinal Neoplasms trials

The registry lists 13 Intestinal Neoplasms studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 10Phase 2 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Oxaliplatin Plus Capecitabine in Treating Patients With Colorectal, Appendix, or Small Bowel CancerCompletedNCT00019773Phase 1
• Flavopiridol in Treating Patients With Refractory CancerCompletedNCT00019344Phase 1
• BMS-247550 in Treating Patients With Advanced CancersCompletedNCT00006221Phase 1
• Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced CancerCompletedNCT00004189Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the PelvisCompletedNCT00003368Phase 1
• Irinotecan Plus Cyclosporine and Phenobarbital in Treating Patients With Solid Tumors or LymphomaCompletedNCT00002759Phase 1